Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

21.90USD
18 Aug 2017
Change (% chg)

$0.10 (+0.46%)
Prev Close
$21.80
Open
$21.65
Day's High
$22.12
Day's Low
$21.40
Volume
421,807
Avg. Vol
809,389
52-wk High
$33.00
52-wk Low
$13.60

Select another date:

Wed, Aug 16 2017

Pharma industry rallies around Acorda's appeal of patent ruling

Trade groups representing the pharmaceutical and biotech industries on Monday urged a federal appeals court to reverse a ruling that invalidated key patents held by Acorda Therapeutics Inc on its multiple sclerosis drug Ampyra.

Deals of the day-Mergers and acquisitions

Aug 7 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Acorda Therapeutics investor calls for company to explore sale

A New York-based hedge fund that owns 17 percent of Acorda Therapeutics Inc on Monday called on the U.S. developer of drugs targeting neurological disorders to explore a sale, according to a regulatory filing with the U.S. Securities and Exchange Commission.

UPDATE 1-Acorda Therapeutics investor calls for company to explore sale

Aug 7 A New York-based hedge fund that owns 17 percent of Acorda Therapeutics Inc on Monday called on the U.S. developer of drugs targeting neurological disorders to explore a sale, according to a regulatory filing with the U.S. Securities and Exchange Commission.

BRIEF-‍Scopia Capital Management LP reports 16.5 pct stake in Acorda Therapeutics as of Aug 4 - SEC filing​

* ‍Scopia Capital Management LP reports 16.5 percent stake in Acorda Therapeutics Inc as of August 4 - SEC filing​

Acorda Therapeutics investor calls for company to explore sale

Aug 7 A New York-based hedge fund which owns 17 percent of Acorda Therapeutics Inc called on the U.S. developer of drugs targeting neurological disorders on Monday to explore a sale of the company, according to a regulatory filing with the U.S. Securities and Exchange Commission.

BRIEF-Acorda Therapeutics Q2 non-GAAP earnings per share $0.29

* Acorda provides financial and pipeline update for second quarter 2017

BRIEF-Christopher James reports 5.9 pct passive stake in Acorda Therapeutics as of June 27, 2017

* Christopher M. James reports a 5.9 percent passive stake in Acorda Therapeutics Inc as of June 27, 2017- sec filing Source text (http://bit.ly/2tz6Pgg) Further company coverage:

BRIEF-Acorda submits new drug application to U.S. Food And Drug Administration

* Acorda submits new drug application to U.S. Food And Drug Administration for inbrijatm (CVT-301, levodopa inhalation powder)

BRIEF-Acorda Therapeutics, in May 2017, filed planned appeal of decision on 4 invalidated patents with U.S. court of appeals for federal circuit

* Acorda Therapeutics -in May 2017, filed planned appeal of decision on four invalidated patents with united states court of appeals for federal circuit

Select another date: